89Zr-bevacizumab PET imaging as predictive biomarker for everolimus efficacy in patients with neuroendocrine tumors - NETPET

niversitair Medisch Centrum Groningen0 个研究点目标入组 14 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•adult patients with metastatic neuroendocrine tumors
•radiological documentation of progressive disease over the past year
•measurable disease according to RECIST criteria
•Adequate bone marrow function as shown by: ANC >= 1.5 x 109/L, Platelets >= 100 x 109/L, Hb > 9 g/dL.
•Adequate liver function: serum bilirubin: <= 1.5 x ULN, ALT and AST <= 2.5x ULN. Patients with known liver metastases: AST and ALT <= 5x ULN.
•Adequate renal function: serum creatinine <= 1.5 x ULN.
•Fasting serum cholesterol <=300 mg/dL OR 7.75 mmol/L AND fasting triglycerides <= 2.5 x ULN. NOTE: In cases where one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication,

•uncontrolled medical conditions (eg, unstable angina, symptomatic heart failure, serious intercurrent infections, uncontrolled diabetes)
•any psychological, familial, sociological condition potentially hampering compliance with the study protocol and follow-up schedule of the study
•Prior therapy with RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus).

发起方